

October 11, 2007

Dear Health Care Professional,

Ortho Biotech Products, L.P., would like to inform you of a business decision, which may affect your practice, regarding the upcoming discontinuation of sales and distribution of SPORANOX[®] (itraconazole) Injection in the United States. Final batches have been manufactured with the last batch expiring in February 2008. Our warehouse anticipates depletion by year-end, therefore, please check with your product supplier for product availability.

SPORANOX Injection is supplied as a kit (NDC 50458-298-01) and is the only SPORANOX formulation being discontinued. SPORANOX[®] oral formulations will continue to be available. SPORANOX[®] Oral Solution will continue to be available through Ortho Biotech Products, L.P. and SPORANOX[®] Capsules through Janssen Ortho-McNeil.

We recognize that this change impacts the prescribing information of the two oral formulations of SPORANOX. The prescribing information will be revised to reflect appropriate changes. Further communication around this will be forthcoming.

Alternative therapies to SPORANOX Injection should be considered. These alternatives include:

- For empiric therapy of febrile neutropenic patients with suspected fungal infections, other FDA-approved products include AmBisome[®] (amphotericin B liposome for injection) and Cancidas[®] (caspofungin acetate for Injection).
- For the treatment of systemic blastomycosis and histoplasmosis, other FDA-approved products include a variety of Amphotericin B preparations, SPORANOX Capsules and Nizoral[®] (ketoconazole) Tablets.
- For the treatment of systemic aspergillosis infections, other FDA-approved products include a variety of Amphotericin B preparations, SPORANOX Capsules, Vfend[®] I.V. (Voriconazole), and Cancidas[®] (caspofungin acetate for Injection).

Please consult the current prescribing information for each product regarding specific antifungal coverage. Additionally, practice guidelines for the treatment of fungal infections, developed by the Infectious Diseases Society of America (IDSA), are available online at <http://www.idsociety.org>.

Ortho Biotech is committed to providing you with the most current product information available for our products. Therefore, we want you to be aware of this decision to help you plan for any impact this decision may have in the management of your patients.

Please refer to the enclosed current full US Prescribing Information for SPORANOX Injection, for Oral Solution, and for Capsules including BOXED WARNINGS.

For additional information related to SPORANOX Injection or Oral Solution, please call Ortho Biotech at 1-888-2-ASK OBI (1-888-227-5624). For additional information related to SPORANOX Capsules, please call Janssen Ortho-McNeil at 1-800-JANSSEN (1-800-526-7736).

Sincerely,



Marc Kamin, MD
Chief Scientific Officer
Ortho Biotech Clinical Affairs, LLC

Trademarks are the property of their respective owners.